FDA wants investigation into Avandia conflict: report

NEW YORK Sat Jul 24, 2010 4:11am IST

Related Topics

Stocks

   

NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.

David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.

Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.

FILED UNDER:

Ebola Fight

REUTERS SHOWCASE

Nifty Above 8,600

Nifty Above 8,600

Nifty hits record high above 8,600; state-run lenders gain  Full Article 

Bhopal Tragedy

Bhopal Tragedy

Bhopal's toxic legacy lives on, 30 years after industrial disaster  Full Article 

Essar Group

Essar Group

Exclusive - Essar's planned oil-for-steel deal tests Iran sanctions  Full Article 

Islamic Fund

Islamic Fund

India gets new Islamic equity fund but debt market still off-limits  Full Article 

Fiscal Deficit

Fiscal Deficit

April-October fiscal deficit nears 90 pct of full-year target  Full Article 

Oil Prices

Oil Prices

Oil hits new four-year low post OPEC as glut looms  Full Article 

Gold Imports

Gold Imports

Nov gold imports seen climbing on expectation of curbs   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage